APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 209 filers reported holding APELLIS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.75 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $422,666,662 | -58.2% | 11,111,111 | 0.0% | 6.59% | -52.0% |
| Q2 2023 | $1,012,222,212 | +38.1% | 11,111,111 | 0.0% | 13.73% | +26.4% |
| Q1 2023 | $732,888,882 | +33.4% | 11,111,111 | +4.6% | 10.86% | +32.3% |
| Q4 2022 | $549,418,750 | -20.6% | 10,625,000 | +4.9% | 8.21% | -35.7% |
| Q3 2022 | $691,538,000 | +56.0% | 10,125,000 | +3.3% | 12.78% | +45.8% |
| Q2 2022 | $443,382,000 | -7.7% | 9,805,000 | +3.8% | 8.76% | -0.0% |
| Q1 2022 | $480,155,000 | +18.7% | 9,450,000 | +10.5% | 8.77% | +27.3% |
| Q4 2021 | $404,507,000 | +143.6% | 8,555,555 | +31.3% | 6.88% | +163.9% |
| Q3 2021 | $166,060,000 | +148.3% | 6,515,000 | +423.2% | 2.61% | +124.3% |
| Q2 2021 | $66,891,000 | +55.9% | 1,245,230 | +24.5% | 1.16% | +57.0% |
| Q1 2021 | $42,910,000 | +475.7% | 1,000,000 | +152.1% | 0.74% | +108.1% |
| Q1 2018 | $7,454,000 | +1.9% | 396,635 | 0.0% | 0.36% | -24.9% |
| Q4 2017 | $7,316,000 | – | 396,635 | – | 0.47% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 3,130,000 | $119,065,200 | 18.29% |
| EcoR1 Capital, LLC | 10,899,859 | $414,630,636 | 13.99% |
| Ally Bridge Group (NY) LLC | 181,805 | $6,915,862 | 8.12% |
| Avoro Capital Advisors LLC | 11,111,111 | $422,666,662 | 6.59% |
| ACUTA CAPITAL PARTNERS, LLC | 244,484 | $9,300,171 | 6.23% |
| Iron Triangle Partners LP | 880,000 | $33,475,200 | 4.89% |
| Cormorant Asset Management, LP | 2,000,000 | $76,080,000 | 4.44% |
| Octagon Capital Advisors LP | 675,000 | $25,677,000 | 3.94% |
| Logos Global Management LP | 750,000 | $28,530,000 | 3.81% |
| Boxer Capital, LLC | 1,726,000 | $65,657,040 | 3.50% |